IGC Pharma (IGS1) Price & Analysis

Q: What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was €0.21 and its highest was €0.53 in the past 12 months.

Q: What is IGC Pharma’s market cap?

IGC Pharma’s market cap is €20.74M.

Q: When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Jun 15, 2026 which is in 115 days.

Q: Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

Q: What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does IGC Pharma have?

IGC Pharma has 95,818,020 shares outstanding.

Q: Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in DE:IGS1

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

5 Followers

IGS1 Stock Chart & Stats

€0.28

<€0.01(0.63%)

At close: Jan 08 4:00 PM EST

€0.28

<€0.01(0.63%)

Day’s Range― - ―

52-Week Range€0.21 - €0.53

Previous CloseN/A

Volume0.00

Average Volume (3M)1.02K

Market Cap

€20.74M

Enterprise Value€23.22M

Total Cash (Recent Filing)€1.10M

Total Debt (Recent Filing)€137.00K

Price to Earnings (P/E)―

Beta0.02

Next Earnings

Jun 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding95,818,020

10 Day Avg. Volume936

30 Day Avg. Volume1,023

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)3.45

Price to Sales (P/S)17.16

P/FCF Ratio-4.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€4.03

Price Target Upside1338.43% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Bears Say

Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma News

IGC Pharma issued notice of allowance by CIPO for IGC-AD1

IGC Pharma (IGC) announced that the Canadian Intellectual Property Office has issued a Notice of Allowance covering the...

3d ago

IGC

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma (IGC) announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America,...

11d ago

IGC

IGC Pharma reaches 70% enrollment in Phase 2 CALMA trial of IGC-AD1

IGC Pharma (IGC) has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial...

18d ago

IGC

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma (IGC) announced the addition of Integrative Clinical Trials, located in Brooklyn, New York, as a new...

29d ago

IGC

IGC Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Igc Pharma, Inc. (IGC) is scheduled to report 3rd quarter earnings on 02/18/2026. Regarding Q3 estimates, Wall Street...

4d ago

IGC

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma (IGC) announced the addition of Dominion Medical Associates, Inc., a Richmond, Virginia-based clinical research site within...

1M ago

IGC

IGC Pharma aligns fiscal year with calendar year

IGC Pharma (IGC) announced that its Board of Directors has approved a change in the Company’s fiscal year...

1M ago

IGC

IGC Pharma Announces Registered Direct Equity Offering Financing

IGC Pharma ( ($IGC) ) has issued an update. On January 5, 2026, IGC Pharma, Inc. entered into...

1M ago

IGC

IGC Pharma raises capital to advance IGC-AD1 Phase 2 trial

IGC Pharma (IGC) entered into a Subscription Agreement with a group of investors for the purchase and sale...

2M ago

IGC

IGC Pharma Adjusts Fiscal Year-End to December 31

IGC Pharma ( ($IGC) ) has provided an announcement. On December 30, 2025, IGC Pharma, Inc. announced that...

2M ago

IGC

Trump Trade: U.S. delays tariffs on Chinese semiconductors

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2M ago

ACB

Trump orders rescheduling of cannabis by end of January, Marijuana Herald says

President Trump has instructed Attorney General Pam Bondi to finalize a decision on marijuana rescheduling by the end...

2M ago

ACB

CGC

Trump Trade: Trump increasing medical marijuana, cannabidiol research

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2M ago

ACB

CGC

IGC Pharma Increases Authorized Shares to 600 Million

IGC Pharma ( ($IGC) ) has issued an update. IGC Pharma, Inc. announced an amendment to its Articles...

2M ago

IGC

IGS1 FAQ

What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was €0.21 and its highest was €0.53 in the past 12 months.

What is IGC Pharma’s market cap?

IGC Pharma’s market cap is €20.74M.

When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Jun 15, 2026 which is in 115 days.

How were IGC Pharma’s earnings last quarter?

Currently, no data Available

Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IGC Pharma have?

IGC Pharma has 95,818,020 shares outstanding.

What happened to IGC Pharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in DE:IGS1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

IGC Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-83.34%

Trailing 12-Months

Asset Growth

-6.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IGC Pharma

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

IGC Pharma (IGS1) Earnings & Revenues

Historic Earnings Reports

IGS1 Earnings Call

Q2 2025

0:00 / 0:00

IGS1 Stock 12 Month Forecast

Average Price Target

€4.03

▲(1338.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","-1":"-€1","0.5":"€0.5","3.5":"€3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.02759796,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.02759796,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.02759796,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.226,0.5184306123076923,0.8108612246153846,1.1032918369230769,1.3957224492307692,1.6881530615384615,1.9805836738461537,2.2730142861538463,2.5654448984615383,2.8578755107692304,3.150306123076923,3.4427367353846154,3.7351673476923075,{"y":4.02759796,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.226,0.5184306123076923,0.8108612246153846,1.1032918369230769,1.3957224492307692,1.6881530615384615,1.9805836738461537,2.2730142861538463,2.5654448984615383,2.8578755107692304,3.150306123076923,3.4427367353846154,3.7351673476923075,{"y":4.02759796,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.226,0.5184306123076923,0.8108612246153846,1.1032918369230769,1.3957224492307692,1.6881530615384615,1.9805836738461537,2.2730142861538463,2.5654448984615383,2.8578755107692304,3.150306123076923,3.4427367353846154,3.7351673476923075,{"y":4.02759796,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.302,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.264,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.258,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.254,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.268,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.254,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.304,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.358,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.344,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.334,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.272,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.246,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.226,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >